Utilizing Digital Therapeutics to Personalize Care & Sustain Engagement

This post was originally published on the Going Digital: Behavioral Health Tech blog on February 3, 2022. Sign up for our weekly newsletter for a lot more behavioral health tech content.

In 2022, digital therapeutics continue to make headlines. As defined by the Digital Therapeutics Alliance , digital therapeutics (DTx) deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.

While there are many digital therapeutics solutions on the market today that target a specific condition, few companies have developed a comprehensive suite of digital therapeutics to integrate a variety of physical and behavioral health issues. One such company is?DarioHealth . They develop digital therapeutics to provide a holistic approach to care, and they have seen increased attention from employers in the past year. The DarioHealth team shared with us more about their digital therapeutics, why it’s advancing the way they provide care, and the outcomes they have seen thus far.?

It seems like employers are starting to gravitate toward solutions that can address multiple chronic conditions on a single platform. Tell us more about Dario's approach and what you are hearing from employers?

Dario was created for one purpose: to make it easy for people to manage chronic conditions. Our digital therapeutics platform was originally designed for diabetes but has since expanded to other commonly co-occurring conditions and those that are reactive to behavior, including diabetes, weight management, musculoskeletal and behavioral health. Today, our platform can monitor the patient’s entire journey and adjust the experience and support as necessary using real-time data from apps and our connected devices.?

Dario Digital Therapeutics are designed with a user-centric approach that provides an integrated experience for people with multiple chronic conditions, looking at their whole health for the best overall results. This is something that is attractive to employers as well. We are hearing from employers of all sizes interested in lessening the burden of managing chronic conditions for their populations and seeking solutions that can provide a better, more holistic experience that can deliver on the promise of lasting results.

What are some of the ways digital therapeutics are advancing the field of digital health??

Digital therapeutics are accelerating progress in both digital and traditional health care by shifting the paradigm from provider-centric to consumer-centric. When Dario launched as a direct-to-consumer solution, we had to design an experience that would keep people engaged with our solution and ultimately, their health, by offering highly personalized support for everyday life. This fundamentally changed how people access and experience care by creating value for the users as well as our partners.

Dario’s digital therapeutics solutions combine real-time data, technologies, and human expertise in a single platform helps create a more effective way to improve whole health. By scaling our consumer-centric approach across multiple conditions, we can deliver a truly holistic approach that addresses the common underlying behaviors for more sustainable change and longer-lasting results.?

How does all of this lead to sustained member engagement and improved outcomes??

Dario’s approach is anchored in billions of data insights from more than 10 years of engagement, enabling a hyper-personalized experience for each person on our platform that adapts to changing needs and preferences to keep people on track. This allows us to effectively attract and retain people in our solutions and on our platform year-over-year. In fact, 80% of our users stick with Dario after the first year.?

That ability to keep people engaged with healthier behaviors leads to outcomes that last, and our 28 clinical studies with plenty of evidence that demonstrates how we can help people sustain positive clinical outcomes for more than two years.?